Tigecycline

Chemical formula: C₂₉H₃₉N₅O₈  Molecular mass: 585.649 g/mol  PubChem compound: 54686904

Therapeutic indications

Tigecycline is indicated for:

Complicated skin and soft tissue infections (cSSTI)

Population group: only adults (18 years old or older)

Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections (cSSTI)

Population group: only adolescents (12 years - 18 years old)

Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections (cSSTI)

Population group: only children (1 year - 12 years old)

Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated intra-abdominal infections (cIAI)

Population group: only adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Tigecycline susceptible species
Tigecycline susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated intra-abdominal infections (cIAI)

Population group: only adolescents (12 years - 18 years old)

Infectious disease of abdomen and additionally at least one of
Tigecycline susceptible species
Tigecycline susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated intra-abdominal infections (cIAI)

Population group: only children (1 year - 12 years old)

Infectious disease of abdomen and additionally at least one of
Tigecycline susceptible species
Tigecycline susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: TYGACIIL Powder for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈